Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266003 · ClinicalTrials.gov registry record · NA
An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment
A NA study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- NA
- Development phase
- 216
- Enrollment target
NCT03266003 is a NA study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 216 participants.
The verdict
NCT03266003, a NA study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- NA
- Development phase
- 216 participants
- Enrollment target
Study Summary
This study is a U.S.-based, 1 site (with 4 clinical settings), randomized controlled trial (with funding from the Centers for Disease Control and Prevention's (CDC) Antibiotic Resistance Solutions Initiative) that will be implemented to evaluate traditional directly observed therapy (DOT) and electronic forms of DOT (eDOT) for tuberculosis (TB) treatment. The trial will assess whether eDOT that employs electronic communication methods, such as video via computer or cellphone, is a non-inferior approach to monitor TB treatment adherence, compared to traditional in-person DOT (ipDOT), in which a trained person is in the physical presence of patients as anti-TB drugs are ingested. ipDOT is the single best intervention proven to be successful when it comes to TB patients' adherence to therapy (which reduces risk of acquired drug resistance). However, ipDOT is resource intensive and many times challenging to facilitate in-person. If eDOT is found to be non-inferior to ipDOT, health departments and other clinicians might be able to provide eDOT to certain populations of TB patients in a more flexible and potentially cost-saving manner.
Interventions
- OTHER Electronic DOT
- OTHER In-person DOT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03266003
The ClinicalTrials.gov registry entry for NCT03266003 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Electronic DOT is the first listed.
NCT03266003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03266003 about?
NCT03266003 is a clinical study titled "An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment". This study is a U.S.-based, 1 site (with 4 clinical settings), randomized controlled trial (with funding from the Centers for Disease Control and Prevention's (CDC) Antibiotic Resistance Solutions Initiative) that will be implemented to evaluate traditional directly observed therapy (DOT) and electr...
What is the current status of trial NCT03266003?
This trial is currently completed. It is a NA study. The enrollment target is 216 participants. The study started on 2017-07-19. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03266003?
The interventions under investigation include: Electronic DOT (OTHER), In-person DOT (OTHER).
Who is sponsoring clinical trial NCT03266003?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.